HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Ranibizumab therapy for choroidal neovascularization secondary to non-age-related macular degeneration causes.

AbstractBACKGROUND:
To investigate the efficacy of ranibizumab therapy for choroidal neovascular (CNV) membranes secondary to conditions other than macular degeneration.
DESIGN:
Prospective case series conducted at the Royal Victorian Eye and Ear Hospital.
PARTICIPANTS:
Twelve-month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, seven had multifocal choroiditis, and eight had other primary causes.
METHODS:
All patients had visual acuity, fluorescein angiogram and optical coherence tomography performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after 1 month, and further injections were given at the treating doctors' discretion.
MAIN OUTCOME MEASURES:
Change in visual acuity and central macular thickness at 12 months was compared with baseline for each of the groups. Local and systemic adverse outcomes were recorded.
RESULTS:
Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and 'other' pathologies, respectively, experienced a three or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. Central macular thickness significantly decreased in the 12-month period for the combined group (P = 0.03). No patient had an adverse systemic side-effect; however, there was one case of endophthalmitis.
CONCLUSIONS:
Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection.
AuthorsRobyn Troutbeck, Roland Bunting, Anton van Heerdon, Melinda Cain, Robyn Guymer
JournalClinical & experimental ophthalmology (Clin Experiment Ophthalmol) 2012 Jan-Feb Vol. 40 Issue 1 Pg. 67-72 ISSN: 1442-9071 [Electronic] Australia
PMID22004186 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2011 The Authors. Clinical and Experimental Ophthalmology © 2011 Royal Australian and New Zealand College of Ophthalmologists.
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Ranibizumab
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Antibodies, Monoclonal, Humanized (adverse effects, therapeutic use)
  • Choroidal Neovascularization (drug therapy, etiology, physiopathology)
  • Choroiditis (complications)
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections
  • Macular Degeneration (complications)
  • Male
  • Middle Aged
  • Myopia (complications)
  • Prospective Studies
  • Ranibizumab
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: